Alpelisib for TEK ‐ and PIK3CA ‐Related Venous Malformations: A Systematic Review
Australasian Journal of Dermatology · 2026-11 · 67 (7)
DOI: 10.1111/ajd.70178 ↗Abstract
ABSTRACT The phosphoinositide 3‐kinase alpha inhibitor alpelisib has been increasingly used in the treatment of venous malformations. In this systematic review of 47 patients with a molecular diagnosis for their venous malformations treated with alpelisib, a partial or complete radiological response was achieved by 77% of evaluable patients and symptomatic improvement in 98%. Adverse effects were predominantly mild, with hyperglycaemia the most frequent, occurring in 58% of patients with available safety data. Trial Registration PROSPERO Registration: CRD420261339549
EUVIMED